Profil
Ronald Marcus worked as an Executive Director-Global Clinical Research at Bristol Myers Squibb Co. from 1991 to 2013.
He then served as the Chief Medical Officer at Spinifex Pharmaceuticals Pty Ltd.
In 2015, he became the Chief Medical Officer & Head-Regulatory Affairs at Avalo Therapeutics, Inc. From 2019 to 2020, he worked as the Chief Medical Officer at Terran Biosciences.
Currently, he is the Senior Vice President-Medical at Karuna Therapeutics, Inc. Dr. Marcus completed his undergraduate studies at the University of Virginia and obtained a doctorate degree from the State University of New York at Buffalo.
Anciens postes connus de Ronald Marcus
| Sociétés | Poste | Fin |
|---|---|---|
| KARA THER | Chief Tech/Sci/R&D Officer | 18/03/2024 |
Terran Biosciences
 Terran Biosciences BiotechnologyHealth Technology Terran Biosciences is a biotech platform company that focuses on developing therapeutics and technologies for patients with neurological and psychiatric diseases. Terran Biosciences is based in New York, NY and has subsidiaries in the United States. The company has built a CNS-focused, tech-enabled drug development platform and is advancing a number of assets that include a late-stage therapeutic for schizophrenia, an FDA-cleared neuroimaging software platform, and a drug design engine that has generated first-in-class and psychedelic-based therapeutics. The company was founded by Samuel Clark, who has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | 01/10/2020 |
| AVALO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 17/11/2017 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2013 |
Spinifex Pharmaceuticals Pty Ltd.
 Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Chief Tech/Sci/R&D Officer | - |
Formation de Ronald Marcus
| University of Virginia | Undergraduate Degree |
| State University of New York at Buffalo | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| AVALO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Spinifex Pharmaceuticals Pty Ltd.
Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
Karuna Therapeutics, Inc.
 Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
Terran Biosciences
Terran Biosciences BiotechnologyHealth Technology Terran Biosciences is a biotech platform company that focuses on developing therapeutics and technologies for patients with neurological and psychiatric diseases. Terran Biosciences is based in New York, NY and has subsidiaries in the United States. The company has built a CNS-focused, tech-enabled drug development platform and is advancing a number of assets that include a late-stage therapeutic for schizophrenia, an FDA-cleared neuroimaging software platform, and a drug design engine that has generated first-in-class and psychedelic-based therapeutics. The company was founded by Samuel Clark, who has been the CEO since incorporation. | Health Technology |
